Literature DB >> 9156043

Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience.

L D Premawardhana1, I A Hughes, G F Read, M F Scanlon.   

Abstract

OBJECTIVE: The outlook for fertility and attaining full adult height is poor in women with congenital adrenal hyperplasia. Such outcomes have followed treatment regimes with variable ages at onset, compliance rates and monitoring. We review final height, vaginal anatomy, ovulation rates and fertility in a group of adult females with the disease. DESIGN AND PATIENTS: Sixteen adult females first diagnosed in infancy or early childhood were reviewed (age range 17-33 years; 11 with salt-wasting disease; five with simple virilizing disease). Case note and clinical review were combined with daily saliva progesterone and weekend 17-hydroxyprogesterone estimation in three consecutive menstrual cycles in a subgroup of eight patients in the ovulation study. MEASUREMENTS AND ANALYSIS: Daily saliva progesterone concentrations were transformed into a cumulative sum curve using a computer program. T95 (defined as the number of days from the start of the luteal phase saliva progesterone rise, in which 95% of total saliva progesterone for the menstrual cycle was obtained) and log C95 (where C95 was defined as 95% of total saliva progesterone for the same cycle) were plotted for each cycle on a boundary diagram obtained from a normal reference population. Weekend saliva 17-hydroxyprogesterone concentrations were compared with published nomograms.
RESULTS: The majority of patients attained a final height below the parental target. Mean standard deviation scores (+/-SEM) and ranges were -1.49 (+/-0.34) and -4.2 to 0.8 for the patients and -0.38 (+/-0.24) and -1.89 to 0.97 for their parents. Of the combined group two-thirds had regular menses and one-third hirsutism; 94% had reconstructive genital surgery with 50% requiring second procedures; 77% had an adequate vaginal introitus (of them 84% in the salt-wasting group and 75% in the simple virilizing group were sexually active). Three of five patients with salt-wasting disease and 2/3 with simple virilizing disease who had both an adequate introitus and were sexually active conceived, resulting in eight pregnancies. In the ovulation study, a 40% ovulation rate was observed with good correlation between plasma testosterone concentrations and degree of control as assessed by weekend 17-hydroxyprogesterone concentrations.
CONCLUSIONS: Our study highlights the potential for improved fertility in female patients with congenital adrenal hyperplasia, who are treated early, comply with long-term treatment and have adequately reconstructed external genitalia. Attaining full adult height potential remains a problem.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156043     DOI: 10.1046/j.1365-2265.1997.1360962.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

Review 1.  Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia.

Authors:  C G Brook
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

Review 2.  Surgery for intersex.

Authors:  S Creighton
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

3.  Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency.

Authors:  Robert C Wilson; Saroj Nimkarn; Miro Dumic; Jihad Obeid; Maryam Razzaghy Azar; Maryam Azar; Hossein Najmabadi; Fatemeh Saffari; Maria I New
Journal:  Mol Genet Metab       Date:  2007-02-01       Impact factor: 4.797

Review 4.  Defects of steroidogenesis.

Authors:  A Biason-Lauber; M Boscaro; F Mantero; G Balercia
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

5.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

6.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

7.  Congenital adrenal hyperplasia: diagnostic advances.

Authors:  T Torresani; Anna Biason-Lauber
Journal:  J Inherit Metab Dis       Date:  2007-08-10       Impact factor: 4.982

Review 8.  Management issues of congenital adrenal hyperplasia during the transition from pediatric to adult care.

Authors:  Jin-Ho Choi; Han-Wook Yoo
Journal:  Korean J Pediatr       Date:  2017-02-27

9.  Getting pregnant with congenital adrenal hyperplasia: Assisted reproduction and pregnancy complications. A systematic review and meta-analysis.

Authors:  Xiaoyan Guo; Yu Zhang; Yiqi Yu; Ling Zhang; Kamran Ullah; Mengxia Ji; Bihui Jin; Jing Shu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-31       Impact factor: 6.055

10.  Malaysian Females With Congenital Adrenal Hyperplasia: Surgical Outcomes and Attitudes.

Authors:  Ani Amelia Zainuddin; Sonia Regina Grover; Chong Hong Soon; Abdul Ghani Nur Azurah; Zaleha Abdullah Mahdy; Loo Ling Wu; Rahmah Rasat; Fatimah Harun; Wee Yan Chia; Khadijah Shamsuddin
Journal:  Front Pediatr       Date:  2019-04-17       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.